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Diabetes mellitus has been recognized since antiquity. It currently affects as many as 285 million people worldwide and results in
heavy personal and national economic burdens. Considerable progress has been made in orthodox antidiabetic drugs. However,
new remedies are still in great demand because of the limited efficacy and undesirable side effects of current orthodox drugs.
Nature is an extraordinary source of antidiabetic medicines. To date, more than 1200 flowering plants have been claimed to have
antidiabetic properties. Among them, one-third have been scientifically studied and documented in around 460 publications. In
this review, we select and discuss blood glucose-lowering medicinal herbs that have the ability to modulate one or more of the
pathways that regulate insulin resistance, 𝛽-cell function, GLP-1 homeostasis, and glucose (re)absorption. Emphasis is placed on
phytochemistry, anti-diabetic bioactivities, and likelymechanism(s). Recent progress in the understanding of the biological actions,
mechanisms, and therapeutic potential of compounds and extracts of plant origin in type 2 diabetes is summarized. This review
provides a source of up-to-date information for further basic and clinical research into herbal therapy for type 2 diabetes. Emerging
views on therapeutic strategies for type 2 diabetes are also discussed.
1. Impact and Pathogenesis of Type 2 Diabetes
Diabetes mellitus is a chronic metabolic disease with life-
threatening complications. The International Diabetes Fed-
eration (IDF) estimates that 285 million people, 6.4% of the
world population, suffered from diabetes in 2010 and this
prevalence will increase to 439 million people, 7.7% of the
world population by 2030 [1]. Over 90% percent of diabetic
patients are diagnosed with type 2 diabetes (T2D) [2, 3].
The cost of health care associated with diabetes continues to
grow and is a huge economic burden for afflicted patients
and countries. In 2007, approximately 17.5 million adults were
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reported to be receiving treatment for diabetes in the USA,
where the estimated cost of diabetes wasUS 174 billion dollars
[4].
Despite considerable progress in scientific studies on T2D
and research and development of antidiabetic agents, the
cause of T2D is not yet fully understood. Mounting evidence
from epidemiological studies suggests that genetic and envi-
ronmental factors are primary causes of T2D. Both factors
contribute to insulin resistance and loss of𝛽-cell function that
result in impairment in insulin action, insulin production,
or both. This impairment results in the development of
hyperglycemia, a major pathological feature of T2D [5].
Such hyperglycemia is detrimental to 𝛽 cells and peripheral
tissues, a condition termed glucotoxicity, which is clinically
relevant as a cause of diabetes-related complications such as
cardiovascular disease, nephropathy, retinal blindness, neu-
ropathy, and peripheral gangrene [6].Therefore,maintenance
of glycemic homeostasis is themost common therapeutic aim
for patients with T2D. Moreover, aberrant lipid metabolism
in adipose and other tissues can cause lipotoxicity, which
can further worsen diabetic complications. The 𝛽 cells in the
pancreas are the key players in glycemic homeostasis. Gluco-
toxicity, lipotoxicity, endoplasmic reticulum (ER)/oxidative
stress, inflammatory mediators, and incretin were reported
tomodulate 𝛽-cell function and survival [7].The relationship
between the causes and pathogenesis of T2D is illustrated in
Figure 1(a).
Insulin is a protein hormone that regulates the meta-
bolism of glucose, fat, and protein in the body [8]. Any defect
in insulin production and action leads to serious metabolic
problems. Pancreatic 𝛽 cells are the only endocrine cells
known to produce insulin. In the development of T2D, 𝛽-
cell function in the presence of increasing hyperglycemia
and insulin resistance declines. This decline may begin early
in the disease and accelerates after compensatory overwork
that drives the progression of T2D. Targeting 𝛽-cell failure
early in disease progression has evolved as a new approach
to treat T2D [9]. Currently, no antidiabetic drugs have been
proven clinically effective for the prevention of 𝛽-cell atro-
phy although thiazolidinediones (TZDs) and glucagon-like
peptide-1 (GLP-1) analogues have reported to be effective in
animals [10–12].Therefore,maintenance and enhancement of
𝛽-cell function have the potential to stabilize, delay, and even
reverse T2D [7]. Specific growth factors, cell cycle mediators,
and nuclear factors have been proposed to regulate 𝛽-cell
homeostasis [13, 14]. New therapeutic classes of diabetes
medications that act to regulate 𝛽-cell function could be
clinically potent in reversing the disease.
Insulin resistance is a condition whereby the body’s cells
become resistant to the action of insulin. Insulin resistance
usually emerges many years before the onset of T2D as
a result of interplay between genetic and environmental
factors [15]. Metabolic hormones (e.g., leptin, adiponectin,
and glucagon), nutrient excess, systemic free fatty acids,
ER stress/oxidative stress, adipose hypoxia, adipose inflam-
mation, and so on account for the generation of insulin
resistance [16]. At the molecular level, fatty acid derivatives,
inflammatory mediators, and free radicals trigger a negative
regulation of IRS-1, PI3K, Akt, GSK-3𝛽, JNK, and other
mediators downstream of insulin receptors.
Loss of glycemic control in T2D patients is an undesirable
and detrimental consequence. Therefore, normalization of
blood glucose by reducing glucose absorption from the gut
and kidney is effective to control glycemic homeostasis in
diabetic patients. Reduction of dietary saccharides or inhi-
bition of glucose from oligosaccharide degradation by 𝛼-
glucosidases in intestines helps to diminish blood glucose
level. Contrarily, the renal tubule can recover 90% of urine
glucose, contributing to glucose homeostasis in the body.
Since sodium glucose cotransporter 2 (Sglt 2) is primarily
expressed in kidney tubules, an Sglt 2 inhibitor was developed
as antihyperglycemic agent.𝛼-Glucosidase inhibitors and Sglt
2 inhibitors have been demonstrated to be clinically effective
against hyperglycemia. Nonetheless, Sglt 2 inhibitor was not
approved by the US Food and Drug Administration (FDA)
because of safety concerns [17].
Incretin consists of glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1),
which are generated by enteroendocrine K-cells and L-cells,
respectively [18, 19]. GLP-1 plays a dominant role in modu-
lating 𝛽-cell function (insulin production and 𝛽-cell prolif-
eration/protection), reducing glucagon secretion, attenuating
gastric emptying, and decreasing appetite/weight gain [20].
Accordingly, the action of incretin is impaired in T2D [21–
23]. GLP-1 has a short half life (<2min) due to its fast cleavage
by dipeptidyl peptidase-4 (DPP-4) [24, 25]. Therefore, GLP-
1 mimetics and DPP-4 inhibitors have been approved by the
FDA as new classes of antidiabetic drugs [26, 27].
More information on the molecular mechanisms under-
lying the pathogenesis of T2D is required for further clinical
success.
2. Pharmacotherapies for T2D and
the Related Challenges
T2D arises from a defect in insulin secretion, insulin action,
and/or both. Hence, T2D therapy has evolved from mono-
therapy using insulin, insulin secretagogues, or sensitizers
alone to combination therapy using insulin/insulin secre-
tagogues plus sensitizers and/or incretin-based drugs. The
mechanisms of action implicated in these remedies include
insulin production, sensitization of the insulin receptor
pathway, and/or GLP-1 secretion. The more pathways the
drugs target, the better the clinical outcome and therapy
seem to be. More recently, manipulation of 𝛽 cells per se
or in combination with other antidiabetic therapeutics has
emerged as a new strategy to ameliorate and, particularly,
cure T2D [7].
By far the most popular approach to treating T2D is
glycemic control in an attempt to reduce complications
and death. When pharmacological methods are used to
interfere with these mechanisms, the percentage of glycosy-
lated hemoglobulin A1c (HbA1c), an indicator of long-term
glycemic control, in medicated T2D patients is suggested to
be below 7%. Since hyperglycemia is implicated in diabetic
complications and death in patients, better regulation of
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Figure 1: Etiology, development, and current therapies for T2D. (a) Genetic and environmental factors are the main contributors to the
development of insulin resistance and impaired glucose tolerance. Under normal glucose tolerance conditions, 𝛽 cells secrete insulin in
response to a surge in glucose after a meal. At the initial stage, 𝛽 cells overwork to compensate for the development of insulin resistance. Later
on, 𝛽 cells are no longer able to secrete enough insulin to overcome insulin resistance. As a result, glucose tolerance is impaired and the disease
progresses from prediabetes to diabetes. Diabetes is characterized as a loss of blood glucose homeostasis, a condition termed hyperglycemia,
in the patients. Glucotoxicity, lipotoxicity, ER/oxidative stress, inflammation, and incretin impairment are risk factors for 𝛽-cell dysfunction.
Besides insulin, insulin releasers, insulin sensitizers, GLP-1 analogues/DDP-4 inhibitors, and a-glucosidase inhibitors and Sglt 2 inhibitors
are common antidiabetic drugs. (b) Insulin releasers (e.g., sulfonylureas such as glibenclamide and glimepiride) can stimulate pancreatic 𝛽
cells to secrete insulin. Insulin sensitizers (TZDs (e.g., rosiglitazone and pioglitazone) and biguanide (metformin)) reduce insulin resistance
in the peripheral tissues. GLP-1 has multiple direct actions on pancreas (insulin and glucagon production) and gastric emptying. Injection
of exogenous GLP-1 (e.g., exenatide and liraglutide) or inhibition of endogenous GLP-1 degradation by DPP-4 inhibitors (e.g., sitagliptin,
vildagliptin, saxagliptin, and linagliptin) can maintain GLP-1 levels. Inhibitors of 𝛼-glucosidases (acarbose) and Sglt 2 (e.g., dapagliflozin and
empagliflozin) reduce glucose absorption in guts and glucose reabsorption in kidney, respectively. All the drugs can diminish hyperglycemia.
∗Sglt 2 inhibitors were disproved by the FDA because of a safety issue.
glycemic maintenance ameliorates progression and sever-
ity of T2D. In the past, several drugs for T2D including
oral antidiabetic agents (OAAs), insulin, and incretin-based
drugs have been developed to control homeostasis of blood
sugar via different mechanisms (Figures 1(a) and 1(b)) [28].
Among OAAs, insulin releasers such as sulfonylurea-type
drugs (e.g., glibenclamide and glimepiride) can directly
stimulate pancreatic 𝛽 cells to secrete insulin, leading to
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lower blood glucose. However, these secretagogues can-
not rescue 𝛽-cell atrophy. In contrast, insulin sensitizers
such as TZDs (e.g., rosiglitazone and pioglitazone) and a
biguanide, metformin, can directly lower insulin resistance
and, subsequently, blood glucose. Glucose (re)absorption
is viewed as an alternative way to lower blood glucose
level. Inhibitors of Sglt 2, dapagliflozin, empagliflozin, and
𝛼-glucosidase inhibitor, acarbose, inhibit the activity of
sodium-glucose cotransporter-2 and 𝛼-glucosidases, respec-
tively, leading to a decrease in glucose (re)absorption via
the renal tubules and the intestine, respectively [17, 29].
Another new class of diabetes therapeutics is the GLP-1
analogues (exenatide and liraglutide) and DPP-4 inhibitors
(e.g., sitagliptin, vildagliptin, saxagliptin, and linagliptin).
This class leverages multiple actions of GLP-1 to lower blood
glucose, including increasing insulin, reducing glucagon, and
gastric emptying [30]. Notably, insulin is still an effective
drug for T2D. Aside frommedication, the importance of diet
and lifestyle management in preventing and alleviating T2D
should not be neglected.
But current antidiabetic agents lack efficacy and also have
undesirable side effects [31]. For instance, insulin secreta-
gogues are frequently linked with weight gain, hypoglycemia,
and inability to protect 𝛽 cells from death [28, 32]. TZDs
and biguanides result in weight gain and kidney toxicity,
respectively. Acarbose usually causes gastrointestinal upset
such as diarrhea and flatulence. Additionally, a clinical trial
of Sglt 2 recently failed due to safety concerns [17]. Despite
the multiple benefits of incretin-based drugs, these drugs are
still accompanied by severe gastrointestinal problems such as
sour stomach, belching, nausea, vomiting, indigestion, and
diarrhea [29]. Even in well-managed patients, daily injection
of insulin cannot match the natural precise timing and
dosing of insulin secretion from the pancreas in response to
hyperglycemia, resulting in severe complications.
Moreover, in addition to lack of efficacy and undesirable
adverse effects, all current antidiabetic agents have a major
shortcoming in that they are only designed to alleviate T2D
and not to cure it. Evidence suggests that targeting one or
two metabolic pathways is insufficient to cure T2D. Drugs
with the ability to target more metabolic pathways seem
to show more encouraging results than those that target a
single pathway, as evidenced by GLP-1. But it should also
be noted that drugs that are effective in targeting metabolic
pathway(s) are often associated with adverse effects [33]. To
ensure patients’ welfare, there is still an obvious need to
develop antidiabetic medicines with satisfactory efficacy and
no severe adverse effects.
3. Herbal Therapy for T2D
Long before the birth of orthodoxWestern medicine, medic-
inal herbs were applied to treat a wide range of disease
categories [34]. Due to emphasis on scientism and other
complicated reasons, Western medicine now prevails over
“traditional” forms of medicine including herbal medicine
systems. Although herbal medicine systems are sometimes
misinterpreted as being unscientific and anachronistic, their
long-term existence proves they are able to compete with
Western drugs at some level. The use of a medicinal herb,
alone or in combination with other herbs, can be thought of
as a type of combination therapy because of the complexity
of the phytochemicals and bioactivities in the plant. Thus,
a single antidiabetic herb with thousands of phytochemicals
may have multiple benefits by targeting several metabolic
pathways and essentially “killing several birds with one
stone.” One study supported this principle by demonstrating
that a combination therapy of orthodox medicine and herbal
medicine exhibited a better (synergistic) effect than either
medicine alone [35].Therefore, herbal medicine can comple-
ment orthodox therapy in T2D and provides hope for a cure.
Medicinal herbs have never become obsolete and still play
a prominent role in human health care. Among them, over
1200 plants have been claimed to be remedies for diabetes [36,
37]. Over 400 plants as well as 700 recipes and compounds
have been scientifically evaluated for T2D treatment [38].
Metformin was developed based on a biguanide compound
from the antidiabetic herb, French lilac, and is now a first-
line drug for T2D [39]. Medicinal herbs contain diverse
bioactive compounds and can have multiple actions on
insulin action, insulin production, or both. In the present
review, we focus on scientific studies of selected glucose-
lowering herbs and phytocompounds and their ability to
target insulin resistance, 𝛽-cell function, incretin-related
pathways, and glucose (re)absorption (Figures 2(a) and 2(b)).
Phytochemistry, antidiabetic bioactivities, and likely modes
of action of the selected plants and compounds are discussed.
4. Selected Medicinal Herbs and
Compounds for T2D
More than 400 plants and compounds have shown antidi-
abetic activities in vitro and/or in vivo. Instead of listing
each extract/compound, here, we select some plant chemicals
and/or extracts with the ability to control blood glucose as
well as to modulate at least one of the following mecha-
nisms involved in insulin resistance:𝛽-cell function, incretin-
related pathways, and glucose (re)absorption. Chemical
structure, antidiabetic activity and action in cells, animal
models, and the results of administration of the plant extracts
and compounds to patients of T2D are discussed. The chem-
ical and biological properties of the compounds discussed in
this section are summarized in Table 1.
4.1. Herbs and Compounds That Regulate Insulin Resistance
4.1.1. Amorfrutins and Licorice. Licorice, the common name
for the plants that comprise the genus Glycyrrhiza, is utilized
as herbal medicine for a wide range of diseases. The ethanol
extract of G. uralensis was found to reduce blood glucose,
fat weight, and blood pressure in rodent models [128]. This
extract also has PPAR-𝛾 activity [128]. Further, amorfrutins
isolated from the licorice, G. foetida, were found to bind
to and activate peroxide proliferator-activated receptor-𝛾
(PPAR-𝛾), a central player in glucose and lipid metabolism
[40]. These compounds lowered blood glucose, fat weight,
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Figure 2:Mechanisms underlying herbal therapies using antidiabetic plants and phytocompounds. (a) Different types of medicinal herbs can
be classified based on their modes of action such as insulin resistance (type 1 herbs), 𝛽-cell function (type 2 herbs), and GLP-1 (type 3 herbs)
and glucose (re)absorption (type 4 herbs). (b)The selected plants and compounds exert their antihyperglycemic effect through targeting one
single mechanism (insulin resistance (type 1 herbs), 𝛽-cell function (type 2 herbs), GLP-1 (type 3 herbs), or glucose (re)absorption (type 4
herbs)) or multiple mechanisms.
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and dyslipidemia [40] indicating that licorice and its active
amorfrutins exert their antidiabetic function via the PPAR-𝛾
pathway.
4.1.2. Dioscorea Polysaccharides and Dioscorea. The rhizome
of Dioscorea is used as a traditional Chinese medicine for
asthma, abscesses, chronic diarrhea, and ulcers [41]. Several
studies on rodent models of diabetes have reported that
Dioscorea extract improves glycemic control and insulin
resistance [41–44]. Further, Dioscorea extract reduced blood
glucose in high fat diet-induced rats [41]. The antidiabetic
mechanism ofDioscorea extract involves reduction of insulin
resistance by diminution of the phosphorylation of ERK and
pS6K and increase of the phosphorylation of Akt and glucose
transporter 4 (Glut4) [41]. Another study demonstrated
that Dioscorea polysaccharides reduced insulin resistance
mediated by inflammatory cytokines as evidenced by the
phosphorylation of insulin receptor substrate (IRS) and Akt
[42].
4.1.3. Anthocyanins and Blueberry. Blueberry (Vaccinium
spp.) was demonstrated to lower systolic and diastolic blood
pressure and lipid oxidation and improve insulin resistance,
diabetes, diabetic complications, and digestion [45, 129–132].
Notably, blueberries contain powerful antioxidants that can
neutralize free radicals that cause neurodegenerative disease,
cardiovascular disease, and cancer [45]. Accordingly, pheno-
lics and anthocyaninswere proposed as active compounds for
diabetes and insulin resistance [45, 46].
One clinical study showed that obese or T2D patients
consuming 22.5 g blueberry, twice a day for 6 weeks, reduced
insulin resistance to a greater extent than those consum-
ing a placebo [47]. The data confirm the beneficial effect
of blueberry on metabolic syndrome. However, the active
compounds related to this claim need further investigation.
4.1.4. Astragalus Polysaccharides and Astragalus. The root of
Astragalus membranaceus has long been used as a Chinese
medicine and shows antioxidant, antidiabetic, antihyperten-
sive, and immunomodulatory activities [133]. The extract of
A. membranaceus was shown to treat diabetes and diabetic
complications [134]. Moreover, treatment with Astragalus
polysaccharides resulted in better glycemic control in dia-
betic rodents via an increase in insulin sensitivity [48–50].
The mode of action of Astragalus polysaccharides includes
Akt activation and upregulation of Glut4 and inhibition of
inflammation via the PTP1B/NF𝜅B pathway [48, 50, 51].
4.1.5. Gastrodia elata. G. elata has been utilized as Chinese
medicine for blood circulation and memory [52]. More
recently, the extract of G. elata has been reported to improve
insulin resistance [52]. Vanillin and 4-hydroxybenzaldehyde
were proposed as the active compounds. Both compounds
reduced insulin resistance through a decrease in fat accumu-
lation in adipose tissues and an increase in fat oxidation and
potentiation of leptin signaling in obese rats [52]. So far, no
clinical study has been conducted in human diabetic patients.
4.1.6. Cinnamon. Both common cinnamon (Cinnamomum
verum and C. zeylanicum) and cassia (C. aromaticum) have
long been used as flavoring agents and in drinks and
medicines worldwide [135]. Cinnamon has traditionally been
used for rheumatism,wounds, diarrhea, headaches, and colds
[136]. Recently, extensive studies have been performed on
the action of cinnamon on diabetes and metabolic syndrome
[135]. Cinnamon was shown to reduce blood glucose via
reduction of insulin resistance and increase of hepatic glyco-
genesis [135, 137]. Cinnamon phenolics were proposed to be
the active compounds in modulation of insulin signaling [53,
138, 139]. Moreover, cinnamaldehyde had antihyperglycemic
and antihyperlipidemic effects on rodent models of diabetes
[53]. This compound from cinnamon extract is thought of
as a potential antidiabetic agent [139]. Unfortunately, the
molecular target of cinnamon and cinnamaldehyde remains
unclear.
4.1.7. Fenugreek. The seeds of fenugreek (Trigonella foenum-
graecum) are used as a food supplement and also have a
long history of medicinal use for labor induction, helping
digestion and improvingmetabolism and health [34]. Animal
studies have shown that extract of fenugreek seeds can lower
blood glucose levels [140, 141]. Fenugreek is considered a
promising agent for diabetes and its complications [34].
The glucose-lowering action of this plant involves reduction
of insulin resistance [142]. Diosgenin, GII, galactomannan,
trigoneosides, and 4-hydroxyisoleucine have been identified
as the active antidiabetic compounds in fenugreek. However,
little is known about the mechanisms of these compounds
[55]. Among them, diosgenin was shown to reduce adipocyte
differentiation and inflammation, implying its action in
reduction of insulin resistance [54]. A clinical study indicated
that fenugreek exerts hypoglycemic control via increasing
insulin sensitivity [143].
4.1.8. Lychee. Lychee (Litchi chinensis) is an evergreen fruit
tree. Its seeds are used as a Chinese herbal medicine for pain,
gastrointestinal diseases, and others. Recently, lychee seed
was reported to have antidiabetic activity in rats [56] and
human patients [144]. Lychee seed extract exerts its action
through reduction of insulin resistance [56]. In addition,
oligonol from lychee fruit showed anti-oxidative activity and,
thus, protected the liver and kidney in T2D animal models
[57, 58].
4.2. Herbs and Compounds That Regulate 𝛽-Cell Function.
In this section, plant chemicals and/or extracts are listed
according to their impact on𝛽 cells.Their chemical structures
and antihyperglycemic activities and actions on 𝛽-cell func-
tion ((re)generation and survival) in cells, animals, and T2D
patients are discussed.The chemical and biological properties
of the compounds discussed in this section are summarized
in Table 1.
4.2.1. Carica papaya and Pandanus amaryllifolius. The etha-
nol extracts of P. amaryllifolius and C. papaya reduced
hyperglycemia in streptozotocin- (STZ-) treated mice [59].
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Histological staining data showed that these extracts sig-
nificantly induced the regeneration of the 𝛽 cells as evi-
denced by reduced blood glucose level [59]. So far, no active
components have been identified. However, the flavonoids,
alkaloids, saponin, and tannin in both plants were speculated
to be bioactive phytochemicals [59].
4.2.2. Conophylline and Tabernaemontana divaricata. Cono-
phylline, a plant alkaloid present inT. divaricata or Ervatamia
microphylla, facilitates differentiation and generation of pan-
creatic𝛽 cells in vitro and in vivo [60–62].This phytochemical
was also shown to decrease the fibrosis of pancreatic islet cells
[63]. Crude extract of T. divaricata was able to increase the
level of blood insulin and reduce the level of blood glucose in
STZ-treated mice [145]. These data imply a plausible role for
conophylline and T. divaricata in 𝛽-cell function.
4.2.3. Kinsenoside. Kinsenoside, a major constituent of
Anoectochilus roxburghii, exhibited hypoglycemic activity in
STZ-treated mice [64]. This effect was partially attributed
to 𝛽-cell repair and/or regeneration. However, the clinical
potential of this compound in 𝛽-cell survival and regenera-
tion awaits further investigation.
4.2.4. Nymphayol. Nymphayol, a plant sterol, was initially
isolated and identified from Nymphaea stellata. One study
showed that this compound promoted the partial genera-
tion of pancreatic islet cells [65]. Oral administration of
Nymphayol significantly diminished the blood glucose level
and increased the insulin content in diabetic rats. In addition,
Nymphayol increased number of 𝛽 cells enormously [65].
However, the impact of this compound on T2D patients is
largely unknown.
4.2.5. Silymarin. Silymarin is a flavonoid mixture composed
of silybin, silydianin, and silychristin, which are active
components of the plant milk thistle (Silybum marianum)
[146]. Aside from antioxidant, anti-inflammatory, and hep-
atoprotective activities, the modes of action through which
silymarin and/or milk thistle exert antidiabetic activity are
not well understood [66–74]. It has been reported that
silymarin can rescue 𝛽-cell function in alloxan-treated rats
[68].
4.2.6. Polyynes andBidens pilosa. B. pilosa is used as an herbal
medicine for a variety of diseases. Ubillas and colleagues
showed that the aqueous ethanol extract of the aerial part of
B. pilosa lowered blood glucose in db/db mice [75]. Based
on a bioactivity-guided identification, 2 polyynes, 3-ß-d-
glucopyranosyl-1-hydroxy-6(E)-tetradecene-8,10,12-triyne,
and 2-ß-d-glucopyranosyloxy-1-hydroxy-5(E)-tridecene-7,
9,11-triyne were identified. Further, a mixture of both
compounds significantly reduced blood glucose levels and
food intake in db/db mice [75]. Another study confirmed
that water extracts of B. pilosa at one and multiple doses
significantly lowered fasting and postmeal hyperglycemia
in db/db mice [76]. The anti-hyperglycemic effect of B.
pilosa was inversely correlated with an increase in serum
insulin levels, suggesting that BPWE acts to lower blood
glucose via increased insulin production. Moreover, B. pilosa
protected against islet atrophy in mouse pancreata. Despite
the variation in the percentage of polyynes, B. pilosa varieties,
B. pilosa L. var. radiate (BPR), B. pilosa L. var. pilosa (BPP),
and B. pilosa L. var. minor (BPM) all displayed antidiabetic
activity in db/dbmice [76]. Another polyyne isolated from B.
pilosa, 2-ß-d-glucopyranosyloxy-1-hydroxytrideca-5,7,9,11-
tetrayne (cytopiloyne) showed better glycemic control than
the previously-mentioned polyynes [53]. Mechanistic study
demonstrated that similar to B. pilosa, cytopiloyne exerts
antidiabetic function through regulation of 𝛽-cell function
involving the increase insulin expression/secretion and islet
protection [53]. Furthermore, cytopiloyne regulated 𝛽-cell
function through a signaling cascade of calcium influx,
diacylglycerol, and protein kinase C𝛼. Collectively, B. pilosa
and cytopiloyne derivatives can treat T2D via acting on 𝛽
cells.
Like all antidiabetic drugs, cytopiloyne failed to prevent
and cure diabetes completely but reduced diabetic com-
plications [53]. Together the data also imply that combi-
nation therapy that targets multiple pathways involved in
metabolism could be a better remedy for T2D.
4.2.7. Gymnema sylvestre. G. sylvestre is an Indian medicinal
herb that has been used to treat diabetes for centuries. The
extract ofG. sylvestrehas been shown to reduce blood glucose.
Its action involves insulin secretion and (re)generation of
pancreatic 𝛽 cells in rodents [77, 78]. G. sylvestre increased
plasma insulin and C-peptide levels and decreased blood
glucose concentrations in T2D patients [79]. Collectively,
this plant exerts its antidiabetic effect via regulation of 𝛽-cell
function.
4.3. Herbs and CompoundsThat Regulate GLP-1 Homeostasis.
The chemical and biological properties of plants and phyto-
chemicals regulating GLP-1 secretion and/or DPP-4 activity
discussed in this section are summarized in Table 1.
4.3.1. Fructans. The American Diabetes Association (ADA)
established a link between high intake of soluble dietary
fiber and improved hyperglycemia and insulin secretion in
T2D patients [147]. Inulins (Raftilose) are soluble dietary
fibers made of short-chain fructans present in the roots of
chicory, Agave tequilana, Dasylirion spp., and so on. One
study showed that inulin-type fructans could prevent obe-
sity, steatosis, and hyperglycemia. Moreover, fructans were
demonstrated to stimulate incretin secretion in the colon of
rats through their fermentation [80, 81]. In addition, 5-week
feeding with inulin significantly lowered body weight gain,
food intake, and blood glucose levels in C57BL/6J mice [82].
An elevation of GLP-1 levels was observed in the portal vein
and proximal colon [82]. It remains unclear whether fructans
can enhance incretin production in humans with T2D.
4.3.2. Monounsaturated Fatty Acid. Epidemiological investi-
gations have established an association between dietary fat
and T2D. A sedentary lifestyle with a diet overly high in fat
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usually accompanies obesity and T2D [148, 149]. However,
fat was found to stimulate incretin secretion [150]. Decrease
in gastric emptying, level of postprandial blood glucose and
insulin, and an increase in plasma GLP-1 level were caused
by ingesting fat before a carbohydrate meal in T2D patients
[86]. In addition, T2Dpatients took controlmeals and control
meals supplemented with olive oil (74% monounsaturated
fatty acid) or butter (72% saturated fatty acid). In contrast to
the control diet, both fat-rich meals induced a 5- to 6-fold
increase in plasma GLP-1 and 3- to 4-fold increase in GIP
[85]. However, no significant differences in the level of blood
glucose, insulin, or fatty acids were observed [85]. In normal
and lean Zucker rats, olive oil enhanced GLP-1 secretion,
leading to improved glycemic tolerance [83, 84]. Data from
humans and rodents suggest that fat, particularly unsaturated
fatty acid, can stimulate GLP-1 secretion.
4.4. Herbs and Compounds That Regulate Glucose Absorp-
tion in the Gut. The chemical and biological properties of
plants and phytochemicals regulating 𝛼-glucosidase activity
discussed in this section are summarized in Table 1.
4.4.1. Serotonin Derivatives and Safflower. Safflower (Car-
thamus tinctorius) seeds are used as a herbal medicine for
menstrual pain, trauma, constipation, and diaphoresis in
Korea and Asian countries [87]. Hydroalcoholic extract of
safflower exhibited antidiabetic properties through enhanc-
ing insulin secretion in alloxan-induced diabetic rats [151].
Two serotonin derivatives isolated from safflower seed were
shown to suppress 𝛼-glucosidase activity to a greater degree
than the positive control acarbose [87].
4.4.2. Butyl-isobutyl-phthalate and Laminaria japonica. Rhi-
zoid of Japanese kelp, L. japonica, has been used to treat
diabetes. Butyl-isobutyl-phthalate, an active compound of
L. japonica, exhibited inhibition of 𝛼-glucosidase activity in
vitro and a hypoglycemic effect on diabetic mice induced by
STZ [88].
4.5. Herbs and Compounds withMultiple Antidiabetic Actions.
Some plants and plant compounds can target multiple
metabolic pathways. The chemical and biological properties
of the compounds discussed in this section are summarized
in Table 1.
4.5.1. Berberine. Berberine, an isoquinoline alkaloid, was
first isolated from Berberis vulgaris. This compound has
multiple functions ranging from inflammation inhibition
and cancer suppression to reduction of metabolic syndrome
and other activities [93, 152–155]. With respect to T2D,
this compound lowered hyperglycemia, increased insulin
resistance, stimulated pancreatic 𝛽-cell regeneration, and
decreased lipid peroxidation in a mouse model of T2D
[89–92]. Thus, it may be useful for treatment of T2D and
other types of diabetes. A meta-analysis study suggests that
berberine per se does not show glycemic control in T2D
patients. Combination treatment of berberine with other
OAAs showed better glycemic control than either treatment
alone. Of note, berberine had a mild antidyslipidemic effect
on patients [94].
4.5.2. Bitter Melon. Bitter melon, the fruit of the plant
Momordica charantia is used in Ayurvedic medicine [156].
The biochemistry and bioactivities associated with the antidi-
abetic effect of the extracts of bitter melon and M. charantia
as a whole have been extensively studied. One in vitro study
showed that bitter melon could increase insulin secretion
from 𝛽 cells. Moreover, immunostaining data indicated
that the juice of the bitter melon increased 𝛽 cells in the
pancreas of STZ-treated rats. Modes of action of bitter melon
and M. charantia include insulin secretion, inhibition of
glucose reabsorption in guts, preservation of islet 𝛽 cells
and their functions, increase of peripheral glucose utilization,
and suppression of gluconeogenic enzymes [38]. Of note,
momorcharin and momordicin, isolated from M. charantia
and its fruit, act to lower blood glucose likely because they
possess insulin-like chemical structures [38].
4.5.3. Capsaicin and Chili Pepper. Chili peppers, the fruits
of the Capsicum plants, are commonly used as food and
medicine. Chili pepper extract exerts an insulinotropic
action, implying its action on 𝛽 cells [157]. Capsaicin, a
pungent component of chili pepper, activates AMPK in 3T3-
L1 preadipocytes [95]. The data suggest that the chili pepper
and its active ingredients prevent T2D via regulation of
insulin resistance and probably 𝛽 cells. However, there is a
discrepancy over the use of capsaicin to treat T2D. Capsaicin
might cause T2D via impairment of insulin secretion [96].
Therefore, precaution should be taken in the use of capsaicin
for T2D.
4.5.4. Ginseng. Ginseng (Panax ginseng) has been viewed
as a panacea in oriental medicine. P. ginseng and North
American ginseng (P. quinquefolius) were demonstrated to
lower blood glucose in rodent models [158, 159]. Roots,
berries, and/or leaves were found effective against T2D in
humans and/or rodents [3, 160–164]. Some clinical studies
have demonstrated that P. ginseng and North American
ginseng improve glycemic control in T2D patients [165, 166].
However, another study reported that neither ginseng had an
antidiabetic effect on diabetic patients [167].This discrepancy
may be the result of a variation in active ginsenosides in
ginseng [168]. The glucose-lowering mechanisms of both
ginsengs may involve a reduction in insulin resistance and
𝛽-cell function [97, 169–173]. Ginsenosides are the primary
constituents present in ginseng roots that are claimed to
benefit health. Extracts of ginseng root have been shown to
protect against apoptosis of the pancreatic 𝛽-cell line, Min-
6 cells [171]. One study proposed that ginseng alters mito-
chondrial function as well as apoptosis cascades to ensure cell
viability in pancreatic islet cells [174]. Moreover, ginsenosides
from ginseng extracts were reportedly responsible for this
protection in vitro. One study reported that ginsenoside Rh2
is an active compound that improves insulin resistance in
fructose-rich chow-fed rats [97]. Besides, ginsenoside Re
was showed to possess antioxidant activity via upregulation
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of glutathione and malondialdehyde in kidney and/or eye
[98]. However, the in vivo protective role of the extracts and
ginsenosides in 𝛽 cells remains to be further verified.
4.5.5. Turmeric. Like many spices such as garlic and ginger,
turmeric shows hypoglycemic and hypolipidemic effects on
diabetic mice [175]. Turmeric also increased postprandial
serum insulin levels to maintain blood glucose levels in
healthy subjects [99]. Curcumin is a major constituent of
the rhizomatous powder of turmeric (Curcuma longa) and
is commonly used as food and medicine in southern Asia.
Curcumin and turmeric rhizomes show a number of bioac-
tivities such as antioxidant, anti-inflammatory, antidiabetic,
and immunomodulatory [176]. Curcumin has been used
to treat T2D [177, 178]. Weisberg and colleagues pointed
out that curcumin reverses many of the inflammatory
and metabolic derangements associated with obesity and
improves glycemic control in mouse models of type 2
diabetes [178]. Chuengsamarn and colleagues showed that
after 9 months of treatment, a curcumin-treated group
showed a better 𝛽-cell function, with higher homeostatic
measurement assessment (HOMA)-𝛽 and lower C-peptide.
Also, the curcumin-treated group showed a lower level of
HOMA insulin resistance (IR). This study demonstrated
that curcumin can prevent T2D in humans [177]. Consis-
tently, another clinical study exhibited that the ingestion
of turmeric increased postprandial serum insulin levels
in healthy subjects. These data suggest that curcumin, a
bioactive compound of turmeric, ameliorates T2D via regu-
lation of insulin resistance and 𝛽-cell function [99]. Further,
turmerin, an anti-oxidant protein identified from turmeric,
was also shown to inhibit 𝛼-glucosidase activity [100]. Over-
all, turmeric exerts antidiabetic actions likely via regulation
of insulin resistance, 𝛽-cell function, and gut absorption.
4.5.6. Dicaffeoylquinic Acids, Matesaponins, and Mate Tea.
Mate tea is made from the leaves of mate, Ilex paraguariensis
(Aquifoliaceae), in South America [101]. Mate has been
claimed to have neuroprotective, antioxidant, hepatopro-
tective, choleretic, diuretic, hypocholesterolemic, antirheu-
matic, antithrombotic, anti-inflammatory, antiobese, and
cardioprotective activities [179–181]. Additionally, mate has
been developed as an herbal supplement to control body
weight [182]. Long-term consumption of mate tea sig-
nificantly increases serum insulin and ameliorates hyper-
glycemia and insulin resistance in mice [101]. Mate also
induces significant decreases in food intake and weight gain
in high fat diet-fed ddYmice. 3,5-O-dicaffeoyl quinic acid and
matesaponin 2, two major constituents of mate, significantly
elevated serum GLP-1 levels in ddY mice. However, neither
inhibited DPP-4 activity [101]. Collectively, these findings
suggest that mate and probably its active compounds act
as an antidiabetic medicine through augmentation of GLP-1
production.
4.5.7. Gingerol and Ginger. Ginger, Zingiber officinale, is
commonly used as an ingredient in foods and medicine.
Compelling data show that ginger extract has hypoglycemic,
insulinotropic, and sensitizer effects on healthy humans and
on experimental animals [103, 183–185]. More recently, Li
and colleagues reported that ginger extract enhanced insulin
release and reduced insulin resistance [103]. One clinical
study reported that consumption of ginger powder, 3 g per
day for 30 days, significantly reduced blood glucose and lipids
in T2D patients [186]. Conversely, another study stated that
consumption of ginger powder, 4 g daily for 3months, did not
alter blood sugar and lipids in patients with coronary artery
disease [187]. This discrepancy may result from the variation
in chemical composition of different ginger preparations.
Gingerol and shogaol are the main active compounds in
ginger extract. Gingerol was shown to attenuate sodium
arsenite-induced T2D. This attenuation is related to islet-cell
protection and increased insulin receptor signaling [102].The
role of shogaol in T2D treatment is not clear although this
compound showed an elevation of glucose uptake in response
to insulin in muscle and adipose cells [103].
4.5.8. Epigallocatechin 3-Gallate (EGCG) and Chinese Tea.
Chinese tea has been used as a beverage and food supplement
since antiquity in China. It is made of the leaves and leaf
buds of the Camellia sinensis species. One of the claimed
health benefits of this tea is reduction of T2D risk and
amelioration of T2D. Chinese green tea and oolong tea can
prevent and/or ameliorate type 2 diabetes in humans [188–
190] and experimental mouse models [191, 192]. EGCG, a
major flavonol in tea, was shown to have antidiabetic activ-
ities in rodents [104, 105]. EGCG appears to have multiple
antidiabetic actions including islet protection, increasing
insulin secretion, decreasing insulin tolerance, and decreas-
ing gluconeogenesis and insulin-mimetic action [104–106].
The role of EGCG in islet protection was shown to protect
against 𝛽-cell death mediated by islet amyloid polypeptide
(IAP) in vitro [193]. EGCG was reported to activate AMPK
in adipocytes [95].
4.5.9. Ishige okamurae. I. okamurae, an edible brown sea-
weed, lowers blood glucose in diabetic db/db mice [88]. Its
mode of action involves reduction of insulin resistance and
regulation of the hepatic glucose metabolic enzymes [88].
Diphlorethohydroxycarmalol, a phlorotannin of I. okamurae,
inhibits the activity of 𝛼-glucosidase and 𝛼-amylase. This
compound also decreases postprandial blood glucose level in
streptozotocin-treated or normal mice [107].
4.5.10. Soybean. Soybeans are thought to be an important
protein source for food. Soybean isoflavones have been
reported to treat atherosclerosis, cancer, osteoporosis, and
others [194]. In addition, soy protein and isoflavonoids
in soybeans improve insulin resistance and enhancement
of insulin release [195, 196]. Genistein is a key isoflavone
present in soybean (Glycine max) and other edible plants
and has been reported to have anticancer, antioxidant, anti-
inflammatory, and antiosteoporosis activities. More recently,
genistein has been reported to treat obesity anddiabetes [197].
This compound preserved islet mass by increasing 𝛽-cell
count, proliferation, and survival in the pancreas [108, 109].
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The data demonstrated that genistein could prevent T2D
via a direct protective action on 𝛽 cells without alteration
of periphery insulin sensitivity [108]. Moreover, its antidi-
abetic mechanism involves activation of protein kinase A
(PKA) and extracellular-signal-regulated kinases (ERK)1/2.
However, another review stated that genistein could activate
AMPK and, in turn, led to a reduction in insulin sensitivity
[95, 110, 111]. Genistein improved diabetic complications such
as vascular dysfunction and wound healing [198, 199]. In a
clinical trial, genistein and/or soybean extract reduced the
risk of T2D in overweight women [200].
Of note, soybean has been demonstrated to promote
the secretion of insulin and GLP-1 [201]. Glyceollins, the
phytoalexins produced by soybeans in response to fungi, were
demonstrated to reduce hyperglycemia. These compounds
could improve glucose-stimulated insulin secretion and pre-
vent apoptosis and dysfunction in 𝛽 cells in the presence
of palmitate [112]. Accordingly, glyceollins enhanced GLP-1
secretion in NCI-H716 cells, an intestinal enteroendocrine L
cell line [112]. Further, the antidiabetic action of glyceollin-
rich soybean extract was confirmed in diabetic mice [121].
In conclusion, soybean and/or its active components can
treat T2D via multiple pathways mainly involving insulin
resistance, 𝛽-cell function, and GLP-1 production.
4.5.11. Rooibos. Rooibos (Aspalathus linearis) is endemic to
South Africa. It can be used as a herbal tea to treat diabetes
in STZ-treated rats [114]. Aspalathin, a dihydrochalcone C-
glucoside of rooibos, reduced hyperglycemia and ameliorated
glucose intolerance through increased glucose uptake and
insulin secretion in db/db mice [113]. Rutin, quercetin-3-O-
rutinoside, is an inhibitor of 𝛼-glucosidase [115]. Rutin also
decreased plasma glucose levels and increased insulin release
in STZ-treated rats [116]. An aspalathin/rutin mixture at a
ratio of 1 : 1 synergistically reduced blood glucose level in dia-
betic rats induced by STZ [114]. Additionally, rutin increased
glucose uptake in hepatocytes in vitro and in mice in vivo,
implying the function of rutin in insulin resistance [117].
Taken together, rooibos and probably its active compounds
can treat T2D via targeting insulin tolerance, 𝛽-cell function,
and inhibition of 𝛼-glucosidase.
4.5.12. Aloe vera. Extract of A. vera reduces hyperglycemia
and hypercholesterolemia in diabetic patients [202, 203].
Similar antidiabetic effects were observed in alloxan- and
STZ-treated animalmodels [204–206]. AloeresinA, an active
compound of A. vera, inhibited 𝛼-glucosidase activity [118].
A. vera and probably its active compounds exert their antidi-
abetic actions via inhibition of 𝛼-glucosidase and intestinal
glucose absorption. In addition, extract of A. vera resulted
in a reduction of hyperglycemia and insulin resistance [207].
As a whole, A. vera and its active components may treat
diabetes via suppression of𝛼-glucosidase activity (gut glucose
absorption) and insulin resistance.
4.5.13. Quercetin. Quercetin is a flavonoid that is widely
distributed in plants and their products. It is commonly used
to treat inflammation, viral infections, cancers, andmetabolic
syndrome. Early studies indicated that quercetin can treat
T2D in STZ- and alloxan-treated mouse models and db/db
mice [119, 120, 208, 209]. More recently, this compound
was shown to lower fasting and postprandial blood glucose
levels in diabetic db/db mice without any alteration in
serum insulin level [210]. Moreover, like acarbose, quercetin
inhibited 𝛼-glucosidase activity [211]. On the other hand,
quercetin also suppressed DPP-4 activity in vitro [208].
However, it remains unclear whether this compound can
stimulate GLP-1 production in vivo. To sum up, the data
suggest that quercetin, a flavonoid commonly found in plants,
controls glycemic control via reduction of intestinal glucose
absorption and, probably, GLP-1 secretion.
4.5.14. Resveratrol. Resveratrol is a stilbene compound, com-
monly found in plants and their products. It has a broad
spectrum of bioactivities such as hepatoprotective, anti-
cancer, anti-inflammatory, immunomodulatory, antidiabetic,
and other activities [212]. Resveratrol has been demonstrated
to treat diabetes [213, 214] and related complications [215–
220] in different rodent models. When used as a T2D
therapy evidence suggests that resveratrol exerts its action
through multiple mechanisms. First, this compound can
activate AMPK and the downstream molecules, leading to
diminution of insulin resistance in db/db mice [121, 122].
It also prevented cell death of pancreatic 𝛽 cells induced
by IAP in culture [123] and in STZ-treated mice [221].
In addition, resveratrol enhanced glucose-mediated insulin
secretion in 𝛽 cells via the activation of SIRT1 [124], one of
the cellular targets of resveratrol [222, 223]. A clinical study
indicated that resveratrol can improve glycemic control in
T2D patients [125]. Collectively, resveratrol ameliorates T2D
and complications via the regulation of insulin resistance and
𝛽-cell functions.
4.5.15. Coffee. Coffee is one of themost commonly consumed
drinks worldwide. Recently, several studies have demon-
strated an association between coffee intake and improve-
ment in glucose tolerance and insulin sensitivity and a lower
risk of T2D [224]. However, the active compound(s) and
responsible target(s) are poorly understood. Accumulating
data imply that constituents other than caffeine are active
in glycemic control and/or insulin sensitivity. A study on
people who consumed caffeinated and decaffeinated coffee
showedno difference in the risk of T2D and insulin sensitivity
in those drinking either type of coffee after 8 weeks of
consumption [225]. However, caffeine improved the function
of adipocytes and the liver [225]. Coffee is one of the major
sources of dietary antioxidants. Roasting at high temperature
can convert chlorogenic acid into quinides, which are known
to reduce blood glucose levels in animal models [126]. In
addition, coffee consumption might also mediate levels of
GLP-1 [127]. Taken together, adequate coffee consumption is
beneficial for T2D and its complications.
4.5.16. Therapeutic Application. The paradigm of antidia-
betic therapy has shifted from monotherapy to combination
therapy. So far, no antidiabetic agents, used alone or in
Evidence-Based Complementary and Alternative Medicine 25
combination, have been able to cure this disease in humans.
A major challenge in the search for efficacious therapies is
that the molecular basis of T2D etiology has not yet been
fully deciphered. Insulin resistance, 𝛽-cell function, glucose
(re)absorption in the gut and kidney, and incretin production
are the primary targets of current drugs. Compelling data
on T2D treatment suggest that multiple targeting of the
previous metabolic pathways is a plausible, albeit not yet
fully developed approach to reversing T2D. Pharmacological
interference of these targets with antidiabetic agents has
undesirable side effects. Due to the richness and complexity
of the compounds in plants, herbal therapy has always
been thought to act on multiple targets in the human
body. Even one single compound can have multiple targets,
as shown by the role of quercetin in inhibition of DPP-
4, 𝛼-glucosidase, and other enzymes. Multiple targeting is
a double-edged sword in diabetes therapies. The multiple
targets associated with antidiabetic herbal medicine make
clinical trials complicated, but such an approach is more
likely to lead to an eventual cure for T2D. In this review, the
antidiabetic potential of the selected glucose-lowering herbs
and their different mechanisms of action were summarized
and discussed. The up-to-date information presented can
be considered a cornerstone for further basic research and
investigation into clinical applications of medicinal plants as
T2D therapies.
5. Conclusions and Perspective
T2D, a disease known to man for many millennia, causes
serious morbidity and mortality in humans. Despite signif-
icant progress in T2D and the development of antidiabetic
drugs, no cures have been found. Medicinal herbs, long
used in alternative and complementary medicine systems,
are an extremely rich source of T2D remedies. Currently,
understanding of the mechanisms through which herbal
therapies mediate T2D is evolving, and they are generally
being viewed as modulating of multiple metabolic pathways.
Based on safety and their multiple targeting actions, herbal
therapies are potent therapeutic means in T2D. Here, we
summarized the chemistry and biology of nearly 40 extracts
and compounds of plant origin that have been demonstrated
to prevent and treat T2D via the regulation of insulin
resistance, 𝛽-cell function, incretin pathways, and glucose
(re)absorption. In addition, the actions, mechanisms and
therapeutic potential of plant compounds and/or extracts,
and new insights into the advantage of herbal therapy,
which simultaneously governs distinct metabolic pathways
immune cells and 𝛽 cells, were discussed for T2D. Systematic
information about the structure, activity, andmodes of action
of these plants and compounds will pave the way for research
and development of antidiabetic drugs.
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